Clinical implementetion of vildagliptin: data from recent studies comparing incretin-based medications
The introduction of DPP-4 inhibitors substantially increased therapeutic options for type 2 diabetes mellitus (T2DM). The unique mechanism of action allows using these agents both as monotherapy and in combination with conventional anti-diabetes drugs. Evidence base for efficacy and safety of DPP-4...
Guardado en:
Autor principal: | Elena Valer'evna Biryukova |
---|---|
Formato: | article |
Lenguaje: | EN RU |
Publicado: |
Endocrinology Research Centre
2014
|
Materias: | |
Acceso en línea: | https://doaj.org/article/8c30a6a6702c497f943e2333951c8c6a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Vildagliptin: the first innovative DDP-4 inhibitor
por: Edvin Villkhauer
Publicado: (2010) -
Expert committee on introduction of incretin-based therapy in Russia: advance and failure
por: Editorial team Diabetes Mellitus
Publicado: (2012) -
Vildagliptin and its role in the treatment of diabetes mellitus
por: Yury Shavkatovich Khalimov
Publicado: (2010) -
First Russian DPP-4 inhibitor Gosogliptin comparing to Vildagliptin in type 2 diabetes mellitus patients
por: Karina Oganesovna Galstyan, et al.
Publicado: (2016) -
Role of incretin based therapies in the treatment of diabetic kidney disease
por: Paola Fioretto, et al.
Publicado: (2018)